Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

Grosso, 2012, Systemic treatment of malignant pleural mesothelioma, Future Oncol, 8, 293, 10.2217/fon.12.14

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Pass, 2012, Biomarkers and prognostic factors for mesothelioma, Ann Cardiothorac Surg, 1, 449

Edwards, 2000, Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems, Thorax, 55, 731, 10.1136/thorax.55.9.731

Travis, 2004

de Assis, 2014, The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma, Biochim Biophys Acta, 1845, 232

Thurneysen, 2009, Functional inactivation of NF2/merlin in human mesothelioma, Lung Cancer, 64, 140, 10.1016/j.lungcan.2008.08.014

Bott, 2011, The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, 43, 668, 10.1038/ng.855

Testa, 2011, Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, 43, 1022, 10.1038/ng.912

Goldstein, 2011, Germline BAP1 mutations and tumor susceptibility, Nat Genet, 43, 925, 10.1038/ng.956

Cheung, 2013, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma, Cancer Genet, 206, 206, 10.1016/j.cancergen.2013.05.018

AJCC, 2010

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059

Cappia, 2008, Prognostic role of osteopontin expression in malignant pleural mesothelioma, Am J Clin Pathol, 130, 58, 10.1309/TWCQV536WWRNEU51

Menges, 2014, Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis, Cancer Res, 74, 1261, 10.1158/0008-5472.CAN-13-2062

Dumont, 2003, The codon 72 polymorphic variants of p53 have markedly different apoptotic potential, Nat Genet, 33, 357, 10.1038/ng1093

Mechanic, 2005, Polymorphisms in XPD and TP53 and mutation in human lung cancer, Carcinogenesis, 26, 597, 10.1093/carcin/bgh344

Han, 2008, Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer, Cancer, 113, 799, 10.1002/cncr.23668

Di Marzo, 2014, Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma, Cell Cycle, 13, 652, 10.4161/cc.27546

Kim, 2009, TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin, Cancer Chemother Pharmacol, 64, 355, 10.1007/s00280-008-0879-3

Yu, 2014, Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair, Proc Natl Acad Sci U S A, 111, 285, 10.1073/pnas.1309085110

Reis, 2005, Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas, Cell Oncol, 27, 319

Tamborini, 2006, Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas, Clin Cancer Res, 12, 6920, 10.1158/1078-0432.CCR-06-1584

Wang, 2012, H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing, Urol Int, 88, 350, 10.1159/000336132

Cacciotti, 2005, SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure, Cancer Res, 65, 5256, 10.1158/0008-5472.CAN-05-0127

Kim, 2005, A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance, Am J Respir Cell Mol Biol, 33, 541, 10.1165/rcmb.2004-0355OC

Wallin, 2011, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway, Mol Cancer Ther, 10, 2426, 10.1158/1535-7163.MCT-11-0446

Dolly, 2013, Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K/MTOR inhibitor, administered to patients with advanced malignant pleural mesothelioma (MPM), J Thorac Oncol, 8, S307

Bianchi, 1995, High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas, Proc Natl Acad Sci U S A, 92, 10854, 10.1073/pnas.92.24.10854

Scoles, 2008, The merlin interacting proteins reveal multiple targets for NF2 therapy, Biochim Biophys Acta, 1785, 32

Riquelme, 2014, Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma, J Thorac Oncol, 9, 998, 10.1097/JTO.0000000000000202

Matullo, 2013, Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study, PLoS One, 8, e61253, 10.1371/journal.pone.0061253